Brazil Court Suspends Sigma Lithium Mine Operations 
Australia Plans New Rules Giving Users Control Over Social Media Feeds 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Spire Healthcare Shares Jump on £1.03 Billion Takeover Deal 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Longsys Raises $903 Million in Hong Kong IPO as Shares Debut Flat 
Add as a preferred source on Google
AstraZeneca (NASDAQ:AZN) has announced plans to acquire biotechnology company EsoBiotec for up to $1 billion, aiming to advance its cell therapy capabilities, particularly for cancer and autoimmune treatments. The deal includes an upfront payment of $425 million and up to $575 million in milestone-based payments. Expected to close in Q2 2025, the acquisition will not impact AstraZeneca’s financial guidance for this year.
This move aligns with AstraZeneca’s strategy to strengthen its position in oncology and cell therapy. The pharmaceutical giant has been expanding aggressively, acquiring China-based Gracell Biotechnologies for $1.2 billion in December 2023 and investing $300 million in Maryland for cell therapy research earlier this year.
CEO Pascal Soriot emphasized that emerging technologies, such as antibody-drug conjugates (ADC) and cell therapy, are becoming key components of AstraZeneca’s drug pipeline. EsoBiotec’s cutting-edge platform enables the genetic modification of immune cells directly inside the body, significantly reducing treatment time from weeks to minutes.
By integrating EsoBiotec’s breakthrough technology, AstraZeneca aims to accelerate the development of next-generation therapies, enhancing its position in the competitive biotech landscape. As the demand for innovative cancer treatments rises, this acquisition reinforces AstraZeneca’s commitment to pioneering advancements in precision medicine and immunotherapy.
